Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Upadacitinib induction therapy in moderately to severely active ulcerative colitis (M14-675)
jRCT2080224070Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Sep 2018
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in autoimmune colitis comparing Upadacitinib with Placebo (2 arms). Started Sep 2018; status: completed.
02
Drugs
upadacitinib
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on jRCT2080224070.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224070.